Gsk Share Discussion Threads

[abdullla] 07/1/2020 15:54

Then what happened to them and where are they now ?

[lippy4] 07/1/2020 15:36

what about their poor clients??

[tradermichael] 07/1/2020 15:27

Disgraced money manager Neil Woodford and his business partner pocketed £13.8 million in dividends in the financial year before the crisis that led to the demise of his fund empire.
The dividend haul was revealed in accounts filed with Companies House for Woodford Investment Management for the last full financial year before the suspension of the flagship equity income fund in June.
Mr Woodford received nearly two-thirds of the payout – around £9 million – for the year to March 31, thanks to his 65% ownership of Woodford Investment Management.
Chief executive Craig Newman picked up £4.8 million.
The pair also bagged £36.5 million the previous year.

[alphorn] 06/1/2020 09:01

fwiw: NOVARTIS has raised U.S. prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya. Most of those increases were in the range of 5.5% to 7%.

[tradermichael] 05/1/2020 17:09

GlaxoSmithKline PLC raised the prices on more than two dozen different therapies, although none by more than by 5%. That includes its shingles vaccine, Shingrix, which sold about $1.7 billion globally in the first nine months of 2019.

A Glaxo spokeswoman confirmed the increases and said net prices for its U.S. products fell about 3.4% on average annually the past five years.

[abdullla] 03/1/2020 16:27

You cant touch me I am part of NHS .

[dr biotech] 03/1/2020 16:08

Not as simple as that. Pharmas are in trumps sights as they have a long history of gouging US customers by typically raising prices 5-10% once or often twice a year. Just have to see the backlash over the cost of the epipen etc. At some point they are going to have to justify that - as they seem to raise their prices at the same time as other majors it does give the appearance of being a cartel.

Can only blame the increasing cost of regulation for so much. There is also the moral side of having a proportion of the population not being able to afford medication. Obviously less of an issue over here but it’s still my tax paying for it.


Not saying there’s an easy answer - regulation is huge and has got stricter even in the last few years.

[tradermichael] 03/1/2020 11:01

So much for a 'Santa' rally!

I'm looking forward to buying in again with the Q4 dividend which should reach accounts on 9 Jan …. ;o)

[tradermichael] 03/1/2020 09:58

I think all companies need to review prices to keep up with increasing costs, so I don't share your mixed feelings. In fact, the GSK review is a lot lower than many of its competitors.

[poikka] 03/1/2020 09:46

"About what, exactly?"

About the previous post, what else?

1. Higher prices good for GSK and shareholders.

2. Higher prices not so good for the sick.

Did that really require an explanation?

[abdullla] 02/1/2020 14:07

Looks like i am also losing something!

[abdullla] 02/1/2020 14:03

With Ftse up 75 what is making GSK loose its footings?

[abdullla] 02/1/2020 13:15

Mixed feelings about Emma .

[crossing_the_rubicon] 02/1/2020 12:14

Mixed feelings presumably because Poikka is:

1) A GSK shareholder, rising prices = greater profits,divi rise?

2) Rising prices might hit his pocket personally(assuming he buys some of the impacted drugs)

[tradermichael] 02/1/2020 11:58

About what, exactly?

[poikka] 02/1/2020 11:37

Mixed feelings about that :/

[tradermichael] 31/12/2019 13:53

GlaxoSmithKline PLC said Tuesday it has completed the sale of two travel vaccines to Danish biotechnology firm Bavarian Nordic AS for up to EUR955 million.

The FTSE 100-listed pharmaceutical firm will receive an initial EUR308 million from the sales of rabies vaccine Rabipur and tick-borne encephalitis vaccine Encepur. The remaining consideration will come in the form of milestone payments, Glaxo said.

Glaxo acquired the two as part of its 2015 purchase of the vaccines business of Swiss peer Novartis AG. The sale of the vaccines supports its increased focus on reinvesting in growth assets as well as simplifying the supply chain of its vaccines unit.
The firm explained: "The decision to divest these brands supports GSK's strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business."

[abdullla] 31/12/2019 12:43

But some have not sold yet and are still sitting on the eggs to hatch but the divi is coming soon,meanwhile have a happy new year.

[lippy4] 31/12/2019 11:31

soon be time to buy again..

[gordogecks] 31/12/2019 10:31

Best wishes for 2020 everyone.

Feel it is going to be a roller coaster one.